Skip to main content

Table 1 Study data used for the evidence synthesis

From: Application of Bayesian evidence synthesis to modelling the effect of ketogenic therapy on survival of high grade glioma patients

Year

First author

Species

Tumor

Treatment

NT + NC

RMSTT

RMSTC

MR

Data source

2014

Han

Humans

GBM

CR+

11 + 23

41.36 ± 4.02

23.70 ± 2.85

1.75 ± 0.27

Figure

2015

Rieger

Humans

GBM

KD

8 + 5

7.25 ± 1.07

5.16 ± 1.29

1.41 ± 0.41

Figure

2018

Santos

Humans

GBM

KD+

17 + 15

10.56 ± 0.94

8.38 ± 1.49

1.26 ± 0.25

Author

2007

Zhou

C57BL/6J mice

CT-2A astrocytoma (syn.)

KD

9 + 7

19.78 ± 0.84

17.71 ± 0.94

1.12 ± 0.08

Author

2007

Zhou

C57BL/6J mice

CT-2A astrocytoma (syn.)

CR

11 + 7

31.82 ± 2.26

17.71 ± 0.94

1.80 ± 0.16

Author

2007

Zhou

BALBc/J SCID mice

U87 glioma (xen.)

KD

7 + 11

19.71 ± 0.78

21.27 ± 1.84

0.93 ± 0.09

Author

2007

Zhou

BALBc/J SCID mice

U87 glioma (xen.)

CR

14 + 11

30.36 ± 1.40

21.27 ± 1.84

1.43 ± 0.14

Author

2008

Marsh

C57BL/6J mice

CT-2A astrocytoma (syn.)

CR

8 + 7

30.50 ± 4.09

18.86 ± 1.20

1.62 ± 0.24

Figure

2010

Stafford

C57BL/6J albino mice

GL261 glioma (syn.)

KD

5 + 5

24.00 ± 0.94

19.00 ± 0.63

1.26 ± 0.06

Author

2011

Maurer

Athymic mice

LNT-229 glioma (xen.)

KD

12 + 12

87.83 ± 4.59

96.90 ± 3.57

0.91 ± 0.06

Author

2012

Abdelwahab

C57BL/6J albino mice

GL261 glioma (syn.)

KD

20 + 19

33.90 ± 5.12

23.32 ± 1.08

1.45 ± 0.23

Author

2012

Abdelwahab

C57BL/6J albino mice

GL261 glioma (syn.)

KD+

11 + 11

97.36 ± 4.93

54.73 ± 9.81

1.78 ± 0.33

Figure

2013

Jiang

Athymic mice

U87 glioma (xen.)

CR

7 + 7

26.71 ± 1.55

18.71 ± 0.85

1.43 ± 0.11

Figure

2014

Rieger

Athymic mice

U87 glioma (xen.)

KD

8 + 8

35.62 ± 0.64

33.88 ± 1.53

1.05 ± 0.05

Author

2014

Rieger

Athymic mice

U87 glioma (xen.)

KD+

8 + 8

57.50 ± 2.28

50.25 ± 2.24

1.14 ± 0.07

Figure

2015

Martuscello

NOD/SCID mice

L0 glioma (xen.)

KD

10 + 11

48.50 ± 5.63

14.55 ± 1.57

3.33 ± 0.53

Figure

2015

Martuscello

NOD/SCID mice

L2 glioma (xen.)

KD

5 + 6

55.20 ± 8.15

25.5 ± 2.38

2.17 ± 0.38

Figure

2016

De Feyter

Fisher rats

9 L glioma (xen.)

KD

10 + 9

34.70 ± 1.63

33.56 ± 1.33

1.07 ± 0.07

Author

2016

De Feyter

Fisher rats

RG2 glioma (xen.)

KD

10 + 11

26.30 ± 1.11

27.36 ± 0.71

0.96 ± 0.05

Author

2016

Lussier

C57BL/6J albino mice

GL261 glioma (syn.)

KD

12 + 11

42.17 ± 2.52

33.09 ± 1.45

1.27 ± 0.09

Figure

  1. Subscript “T” denotes treatment group, “C” control group. CR/KD Calorie restriction/ Ketogenic diet as monotherapy, CR+/KD+ Calorie restriction/ ketogenic diet combined with another therapy, syn. syngeneic transplant, xen. xenogeneic transplant